Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Capital Expenditures: 2009-2024

Historic Capital Expenditures for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $246.5 million.

  • UNITED THERAPEUTICS's Capital Expenditures rose 175.16% to $210.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $434.3 million, marking a year-over-year increase of 82.10%. This contributed to the annual value of $246.5 million for FY2024, which is 6.99% up from last year.
  • UNITED THERAPEUTICS's Capital Expenditures amounted to $246.5 million in FY2024, which was up 6.99% from $230.4 million recorded in FY2023.
  • UNITED THERAPEUTICS's 5-year Capital Expenditures high stood at $246.5 million for FY2024, and its period low was $59.3 million during FY2020.
  • Moreover, its 3-year median value for Capital Expenditures was $230.4 million (2023), whereas its average is $205.2 million.
  • In the last 5 years, UNITED THERAPEUTICS's Capital Expenditures declined by 29.15% in 2020 and then surged by 103.71% in 2021.
  • UNITED THERAPEUTICS's Capital Expenditures (Yearly) stood at $59.3 million in 2020, then soared by 103.71% to $120.8 million in 2021, then climbed by 14.90% to $138.8 million in 2022, then soared by 65.99% to $230.4 million in 2023, then grew by 6.99% to $246.5 million in 2024.